Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0816120120150010044
Korean Journal of Pediatric Gastroenterolology and Nutrition
2012 Volume.15 No. 1 p.44 ~ p.51
Role of Tumor Necrosis Factor-a Promoter Polymorphism and Insulin Resistance in the Development of Non-alcoholic Fatty Liver Disease in Obese Children
Yang Hye-Ran

Ko Jae-Sung
Seo Jeong-Kee
Abstract
Purpose: Tumor necrosis factor-Ձ (TNF-Ձ) polymorphism has been suggested to play an important role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) in obese adults, and known to be a mediator of insulin resistance. In this study, we evaluated the role of TNF-Ձ promoter polymorphisms and insulin resistance in the development of NAFLD in obese children.

Methods: A total of 111 obese children (M£ºF=74£º37; mean age, 11.1¡¾2.0 yrs) were included. The children were divided into 3 groups: controls (group I, n=61), children with simple steatosis (group II, n=17), and children with non-alcoholic steatohepatitis (group III, n=33). Serum TNF-Ձ levels, homeostasis model assessment of insulin resistance (HOMA-IR), and TNF-Ձ -308 and -238 polymorphisms were evaluated.

Results: There were no differences in TNF-Ձ polymorphism at the -308 or the -238 loci between group I and group II + III (p=0.134 and p=0.133). The medians of HOMA-IR were significantly different between group I and group II + III (p=0.001), with significant difference between group II and group III (p=0.007). No difference was observed in the HOMA-IR among the genotypes at the -308 locus (p=0.061) or the -238 locus (p=0.207) in obese children.

Conclusion: TNF-Ձ promoter polymorphisms at the -308 and -238 loci were not significantly associated with the development of NAFLD in children; nevertheless, insulin resistance remains a likely essential factor in the pathogenesis of NAFLD in obese children, especially in the progression to NASH.
KEYWORD
TNF-Ձ polymorphism, Insulin resistance, Fatty liver, Obesity, Child
FullTexts / Linksout information
  
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø